Sufentanil transdermal - tesa Labtec

Drug Profile

Sufentanil transdermal - tesa Labtec

Alternative Names: Sufentanil TDS

Latest Information Update: 09 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Labtec
  • Developer hameln rds; tesa Labtec
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer pain; Pain

Most Recent Events

  • 08 Mar 2017 Discontinued - Phase-I for Pain in Germany before March 2017 (Transdermal)
  • 08 Mar 2017 Discontinued - Phase-II for Cancer pain in Slovakia before March 2017 (Transdermal)
  • 27 Jul 2015 No recent reports on development identified - Phase-I for Pain in Germany (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top